Why not start with thalidomide?

Journal of Clinical Oncology

Volumn 21, Issue 11, 2003, Pages 2211-2214

  Loprinzi, Charles ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; THALIDOMIDE; ANGIOGENESIS INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; CONSULTATION; DOSE RESPONSE; DRUG EFFICACY; HEALTH CARE PERSONNEL; HIP FRACTURE; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL STAFF; MULTIPLE MYELOMA; PHYSICIAN; PRIORITY JOURNAL; TERATOGENICITY; TREATMENT RESPONSE; CASE REPORT; CONTROLLED CLINICAL TRIAL; DECISION MAKING; FEMALE; MEDICAL ETHICS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ANGIOGENESIS INHIBITORS; DECISION MAKING; ETHICS, MEDICAL; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS; THALIDOMIDE; UNITED STATES;

EID: 0037868157     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.113     Document Type: Article

References (17)

1. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
2. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
3. Rajkumar SV, Dispenzieri A, Fonseca R, et al: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274-1276, 2001
4. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
5. Multiple Myeloma and Thalidomide. Accessed April 10, 2003. hup:// www.cnn.com/2000/HEALTH/mayo/09/18/multiple.myeloma/index.html
6. Myeloma Treatment and Thalidomide. Accessed April 10, 2003. http://www.multiplemyeloma.org/treatments/3.02.02.asp
7. Rajkumar SV, Mesa R, Tefferi A: A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 11:33-47, 2002
8. Weber DM, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
9. Mitka M: Thalidomide battles myeloma (news). JAMA 286:909, 2001
10. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
11. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
12. Fisher RI, DeVita VT Jr, Hubbard SM, et al: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med 98:304-309, 1983
13. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
14. Laine C: Postmenopausal hormone replacement therapy: How could we have been so wrong? Ann Intern Med 137:290, 2002
15. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
16. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
17. Clapesattle H: The Doctors Mayo. Rochester, MN, Mayo Foundation for Medical Education and Research, 1990